24 June 2022 : Clinical Research
Medroxyprogesterone Acetate for Abnormal Uterine Bleeding Due to Ovulatory Dysfunction: The Effect of 2 Different-Duration Regimens
Rukiye Ada Bender
12ABCDEFG*
DOI: 10.12659/MSM.936727
Med Sci Monit 2022; 28:e936727
Table 2 The menstruation pattern, need for prolonged medical treatment or surgical intervention, and hemogram parameter results of the women after retrospective analysis.
| MPA* administration days | Group A (n=22) | Group B (n=30) | p-value | ||
|---|---|---|---|---|---|
| 11th & 25th | Min–Max | 16th & 25th | Min–Max | ||
| Regular | 11 (%50) | 25 (%83.3) | |||
| Oligomenorrhea | 0 | 1 (%3.3) | |||
| Abnormal uterine bleeding | 11 (%50) | 5 (%16.7) | |||
| 6 (%27.2) | 0 | ||||
| 0.39 | |||||
| Hysteroscopy | 3 (%13.6) | 1 (%3.3) | |||
| Hysterectomy | 5 (%22.7) | 4 (%13.3) | |||
| 11.90±1.54 | 9.7–14.8 | 12.35±1.28 | 8.21–14.4 | 0.25 | |
| 6.7±4.1 | 29.8–44.8 | 37.4±3.39 | 26.4–43.7 | 0.55 | |
| * Medroxyprogesterone acetate. | |||||